

## Hydromer, Inc<sup>®</sup> Files Annual Reports for Fiscal Years 2020 and 2021.

**Concord, NC, September 10, 2021** -- Hydromer, Inc. (OTCMKTS: HYDI), a leading global manufacturer of custom industrial and medical device surface modification technologies, announced that it has filed with the OTC Markets Group the Company's annual reports and accompanying financial results for the Fiscal Years ended on June 30, 2020, and June 30, 2021.

*Fiscal Year 2020 was the Company's most transformational year in some time and one that required great adaption to a series of challenges. "We started Fiscal Year 2020 winding down operations in our 40-year-old manufacturing plant in New Jersey (NJ), while concurrently standing up our newly designed and constructed facility in North Carolina (NC), both of which were enormous undertakings but strategic to allow us to reduce our expenses and increase our efficiencies going forward."* said Peter M. von Dyck, CEO – Hydromer, Inc. From an operations standpoint, Fiscal Year 2020 was filled with great complexities and wonderful opportunities, *"our primary complexity was the successful transition from of our older U.S. Food and Drug Administration (FDA) / International Organization for Standardization (ISO) certified New Jersey (NJ) facility into our brand new and custom designed facility in Concord, NC. Our primary objective was to achieve this transition with minimum impact to our customers. The North Carolina (NC) transition was a very detail-intensive operation; our team worked with architects, builders, and government officials to ensure the optimal facility design while obtaining the required permits and approvals from the various local governmental certifying agencies and departments."* said Martin C. von Dyck, COO – Hydromer, Inc.

Conversely, throughout Fiscal Year 2021, the COVID-19 pandemic negatively impacted the Company's ability to generate steady business with new customers, and adversely affected the Company's recurring business with core customers. *"Most of our customers reported their larger plants and offices around the globe on lockdowns, with most of their workforce either working from home or with significantly reduced capacity. During the fiscal year, our business-to-business (B2B) healthcare customers also reported reduced sales of medical*

*devices coated with Hydromer's proprietary formulations as regulations implemented at hospitals and clinics globally to address the COVID-19 pandemic delayed the execution of most medical procedures that typically utilize such devices." said Peter M. von Dyck, CEO – Hydromer, Inc. "To better monitor the ongoing economic effects of the COVID-19 pandemic on our finances and operations, we have implemented required cost reduction strategies and have made changes to restructure our operating costs footprint to overcome the present trying times, and to withstand future volatile market conditions." said Peter M. von Dyck, CEO – Hydromer, Inc.*

Operationally, during Fiscal Year 2021 the Company focused on manufacturing improvements, and equipment & processes upgrades and modernizations to meet the requirements of the evolving markets during the COVID-19 pandemic and beyond, *"we focused on strategic core business and targeted our research and development efforts on re-building and aligning our equipment and technologies to best meet our sales and customers' new objectives. We will continue this process during Fiscal Year 2022."* said Martin C. von Dyck, COO – Hydromer, Inc. He closed by underscoring that *"Fiscal Year 2021 has set the foundation for strong operating capabilities for the Company that well surpasses our customers' current production capabilities."* In Fiscal Year 2022, moving past the difficult times posed by the COVID-19 pandemic, the Company continues to focus on manufacturing critically needed healthcare products, using its highly demanded, most advanced and well proven polymer technologies. *"We are the lean provider of specialized polymers surface modification technologies."* said Peter M. von Dyck, CEO – Hydromer, Inc.

The Company's annual reports for the Fiscal Years 2020 and 2021 may be accessed directly from the OTC Markets website at <https://www.otcmarkets.com/stock/HYDI/disclosure>. The annual reports for the Fiscal Years 2020 and 2021 are also uploaded to the company's website at <https://hydromer.com/investor-relations/>.

Hydromer ®

Hydromer's legacy of innovation provides many technologies and areas of expertise that are in high demand, from anti-microbial coating capabilities, line of alcohol and plant-based sanitization products, proprietary technologies, including a line of anti-fog and condensation control products; the company expects continual increase in global demand for those products given the current more infection control minded ecosystem.



#### About Hydromer®

Hydromer®, Inc & Subsidiary (the "Company") is an ISO 9001:2015 leading global business-to-business (B2B) surface modification and coating solutions provider offering polymer research & development, and manufacturing services capabilities for a wide variety of applications. We are a U.S. public corporation domiciled in Concord, NC. Our customers are located across the United States of America, Europe, and Asia-Pacific. The Company was established in 1980, originally incorporated in the State of New Jersey. We are a U.S. Food and Drug Administration (FDA), Good Manufacturing Practice (GMP), International Organization for Standardization (ISO) 13485, and International Organization for Standardization (ISO) 9001 production facility. For over four decades, the Company has developed value-added solutions to serve businesses in domestic and international markets, in a wide range of industries. Driven by the new corporate leadership's strategic business objectives and goals, the Company's operations were restructured into two distinct business segments: industrial and medical. We manage numerous global B2B services such as, coating services, research and development, analytical testing, technology transfer, and dedicated machinery building, installation, and support. We have successfully developed over 90 proprietary formulations and have secured over 400 patents worldwide at separate times throughout our history including, anti-microbial, anti-fog, anti-frost, condensation-controlling, hydrophilic and thromboresistant coatings. The Company's track record of innovation plays an integral part in over four decades of sustainable revenues from product sales and services, royalties, and support agreements.

<https://hydromer.com/>

[info@hydromer.com](mailto:info@hydromer.com)

